SeaCrest Wealth Management LLC Has $784,000 Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)

SeaCrest Wealth Management LLC grew its position in Emergent BioSolutions Inc. (NYSE:EBS) by 19.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 114,995 shares of the biopharmaceutical company’s stock after buying an additional 18,995 shares during the period. SeaCrest Wealth Management LLC owned approximately 0.22% of Emergent BioSolutions worth $784,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in EBS. Allspring Global Investments Holdings LLC lifted its position in Emergent BioSolutions by 1.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock valued at $1,105,000 after acquiring an additional 6,724 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Emergent BioSolutions by 84.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock valued at $6,898,000 after acquiring an additional 1,312,934 shares in the last quarter. Jump Financial LLC bought a new stake in Emergent BioSolutions in the 4th quarter valued at $58,000. Dynamic Technology Lab Private Ltd bought a new stake in Emergent BioSolutions in the 4th quarter valued at $232,000. Finally, Oxford Asset Management LLP bought a new stake in Emergent BioSolutions in the 4th quarter valued at $67,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Stock Down 21.2 %

NYSE:EBS traded down $2.56 on Tuesday, hitting $9.54. 4,920,062 shares of the company’s stock were exchanged, compared to its average volume of 3,894,810. The firm has a 50-day moving average price of $9.03 and a 200-day moving average price of $5.22. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.08 and a quick ratio of 0.55. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The company has a market cap of $499.92 million, a P/E ratio of -0.87 and a beta of 1.62.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.35). Emergent BioSolutions had a negative return on equity of 18.53% and a negative net margin of 47.68%. The business had revenue of $254.70 million for the quarter, compared to the consensus estimate of $199.47 million. During the same period last year, the firm earned ($1.06) earnings per share. As a group, analysts expect that Emergent BioSolutions Inc. will post -1.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Benchmark reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a research report on Friday.

Insider Activity

In other news, Director Kathryn C. Zoon sold 10,000 shares of the company’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $6.11, for a total value of $61,100.00. Following the sale, the director now directly owns 54,482 shares of the company’s stock, valued at approximately $332,885.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.20% of the stock is owned by insiders.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.